Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Thompson on antihistamine switches

This article was originally published in The Tan Sheet

Executive Summary

HHS Secretary Tommy Thompson says he favors switching some low- and non-sedating antihistamines OTC. Speaking after a House committee hearing Feb. 6, he adds that progress has been made on the issue; FDA has reportedly sent its decision regarding a forced switch of Schering-Plough's Claritin, Aventis' Allegra and Pfizer's Zyrtec to Thompson's office (1"The Tan Sheet" Feb. 4, 2002, p. 3). Switch issue also appears to have attracted White House's attention; Mark McClellan, MD/PhD, health advisor to President Bush, says at American Enterprise Institute briefing Feb. 4 that "FDA has and will continue to look closely at OTC determination policies to see if there are ways we can improve patient safety while helping [keep] costs down"...

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts